Medtox Scientific, Inc. v. Morgan Capital L.L.C.

50 F. Supp. 2d 896, 1999 U.S. Dist. LEXIS 8690, 1999 WL 359758
CourtDistrict Court, D. Minnesota
DecidedJune 3, 1999
DocketCiv. 97-253 ADM/AJB
StatusPublished
Cited by3 cases

This text of 50 F. Supp. 2d 896 (Medtox Scientific, Inc. v. Morgan Capital L.L.C.) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Medtox Scientific, Inc. v. Morgan Capital L.L.C., 50 F. Supp. 2d 896, 1999 U.S. Dist. LEXIS 8690, 1999 WL 359758 (mnd 1999).

Opinion

MEMORANDUM OPINION AND ORDER

. MONTGOMERY, District Judge.

I. INTRODUCTION

Plaintiff Medtox Scientific, Inc. (“Med-tox”), fik/a Editek, Inc. (“Editek”), 1 filed this action on January 31, 1997, to recover alleged short-swing insider profits realized by Defendant Morgan Capital L.L.C. (“Morgan Capital”) and its alleged control persons, Defendants Alex and David Bis-tricer (“Bistricers”), on a series of 1996 transactions involving Editek stock. On August 4, 1997, Judge Richard H. Kyle of this Court dismissed Plaintiffs Complaint for failure to state a claim upon which relief can be granted. See Editek v. Morgan Capital, L.L.C., 974 F.Supp. 1229 (D.Minn.1997) (“Editek I”). Plaintiff appealed the decision, and on July 24, 1998, the Eighth Circuit Court of Appeals reversed the district court judgment and remanded the case for further proceedings. See Editek v. Morgan Capital, L.L.C., 150 F.3d 830 (8th Cir.1998) (“Editek II”). Judge Kyle subsequently recused himself from the case pursuant to 28 U.S.C. § 455, *898 and it was reassigned to the undersigned United States District Judge. The matter is currently before the Court on Defendants’ Motion to Dismiss the Complaint and Plaintiffs Motion for Partial Summary Judgment. For the reasons set forth, below, Defendants’ motion is denied and Plaintiffs motion is granted.

II. DEFENDANTS’ 12(b)(6) MOTION

Rule 12 of the Federal Rules of Civil Procedure provides that a party may move to dismiss a complaint for failure to state a claim upon which relief can be granted. Fed.R.CivJP. 12(b)(6) (“Rule 12(b)(6)”). In considering a motion to dismiss, the pleadings are construed in a light most favorable to the plaintiff, and the facts alleged in the complaint must be taken as true. See Hamm v. Groose, 15 F.3d 110, 112 (8th Cir.1994); Ossman v. Diana Corp., 825 F.Supp. 870, 879-80 (D.Minn.1993). Any ambiguities concerning the sufficiency of the claims must be resolved in favor of the nonmoving party. See Ossman, 825 F.Supp. at 880. A complaint should be dismissed pursuant to Rule 12(b)(6) “only if it is clear that no relief can be granted under-any set of facts that could be proved consistent with the allegations.” Frey v. City of Herculaneum, 44 F.3d 667, 671 (8th Cir.1995) (citations omitted). In other words, “[a] motion to dismiss should be granted as a practical matter ... only in the unusual case in which the plaintiff includes allegations that show on the face of the complaint that there is some insuperable bar to relief.” Frey, 44 F.3d at 671.

A. The Complaint

On or. about February 1, 1996, Editek, a Delaware corporation with its principal place of business in Minnesota, issued shares of Convertible Preferred Stock (“Preferred Stock”)' in an offering conducted under Section D of the Securities Act of 1933 (“the Offering”). Compl. ¶¶2, 11. At the option of the holder, each share of Preferred Stock was convertible to Editek common stock (“Common Stock”) at a price equal to the average closing price of the shares of Common Stock for the five trading day period preceding the date notice of conversion was given to Editek by such holder. Id. ¶-12. Consequently, the number of shares of Common Stock that the Preferred Stock would buy floated with the average-trading price of the Common Stock. As the trading price of the Common Stock declined, the number of shares of Common Stock that the Preferred Stock would buy increased, and vice-versa. The right to convert the Preferred Stock was not exercisable until 60 days after issuance of the shares. Id.

Morgan Capital,, a limited liability corporation with offices in Brooklyn, New York, purchased Preferred Stock from Editek in the Offering. Compl. ¶¶ 3, 13. At the time of its purchase, the number of shares of Common Stock that Morgan Capital would have received upon conversion of its Preferred Stock (were it allowed to immediately convert the stock) would have been less than ten percent of the outstanding shares of Editek’s Common Stock. Id. 1113.

On March 28, 1996, as a result of a decline in the price of the Common Stock, the amount of shares of Common Stock that Morgan Capital would have received upon conversion of its Preferred Stock (again, were it allowed .to convert the stock at such time) would have been greater than ten percent of the outstanding, shares of Editek’s Common Stock. Compl. ¶ 14. March 30, 1996, marked the first day upon which Morgan Capital was eligible to convert its Preferred Stock into Common Stock. See Editek II, 150 F.3d at 832.

On May 1, 1996, Morgan Capital converted all of its Preferred Stock into Common Stock. Compl. ¶ 15. The Common Stock that Morgan Capital received in the conversion amounted to greater than ten percent of the outstanding shares of Edi-tek’s Common Stock. Id. Morgan Capital then sold a portion of its shares of Common Stock on five separate occasions in May and June 1996, realizing a profit of at least $500,000. Id. ¶¶ 17,18.

*899 B. Section 16(b)

In its sole claim for relief, Editek alleges that Morgan Capital’s conduct violated Section 16(b) of the Securities Exchange Act of 1934 (“the Exchange Act”), 15 U.S.C. § 78p(b). Section 16(b) was enacted to prevent corporate “insiders” from abusing their fiduciary positions “by using confidential corporate information to aid their personal market activities.” Petteys v. Butler, 367 F.2d 528; 532 (8th Cir.1966), cert. denied 385 U.S. 1006, 87 S.Ct. 712, 17 L.Ed.2d 545 (1967). The statute provides in relevant part as follows:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
50 F. Supp. 2d 896, 1999 U.S. Dist. LEXIS 8690, 1999 WL 359758, Counsel Stack Legal Research, https://law.counselstack.com/opinion/medtox-scientific-inc-v-morgan-capital-llc-mnd-1999.